Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin(2A) receptor antagonist MDL 100,907

Biological Psychiatry

Volumn 44, Issue 6, 1998, Pages 508-515

  Wadenberg, Marie Louise G ^a,c   Hicks, Paul B ^a   Richter, J Travis ^a   Young, Keith A ^b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Veterans Healthcare System   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Atypical antipsychotic drugs; Conditioned avoidance response behavior; Dopamine D2 receptor; Rat; Serotonin(2A) receptor

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE RECEPTOR; RACLOPRIDE; SEROTONIN 2A ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR BLOCKING; SCREENING TEST;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOROBENZENES; MALE; PIPERIDINES; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SALICYLAMIDES; SEROTONIN ANTAGONISTS;

EID: 0032530496     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00424-1     Document Type: Article

References (43)

1. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathé J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol. 352:1995;374-385.
2. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats Inhibition by neuroleptics and correlation to dopamine receptor blockade . Acta Pharmacol Toxicol. 51:1982;321-329.
3. Ayd F.J., Settle E.C. Jr. Trazodone A novel, broad-spectrum antidepressant . Mod Probl Pharmacopsychiatry. 18:1982;49-69.
4. Baldessarini R (1996): Drugs and the treatment of psychiatric disorders: Psychosis and anxiety. In: Molinoff PB, Ruddon RW, Goodman Gilman A, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, pp 399-430.
5. Carman J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia A meta-analysis . Int Clin Psychopharmacol. 10:1995;207-213.
6. Courvoisier S. Pharmacodynamic basis for the use of chlorpromazine in psychiatry. J Clin Exp Psychopathol Q Rev Psychiat Neurol. 17:1956;25-37.
7. Courvoisier S., Ducrot R., Julou L. Nouveaux aspects expérimenteaux de l'activité centrale des dérivés de la phenothiazine. Garattini S., Ghetti V. Psychotropic Drugs. 1957;373-391 Elsevier, Amsterdam.
8. Davidson A.B., Weidley E. Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats. Life Sci. 18:1976;1279-1284.
9. 2 receptor antagonist. Soc Neurosci Abstr. 16:1990;1037.
10. Duinkerke S.J., Botter P.A., Jansen A.A.I., van Dongen P.A.M., van Haaften A.J., Boom A.J., et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia A placebo-controlled double-blind trial . Br J Psychiatry. 163:1993;451-455.
11. Farde L., Wiesel F.A., Nordström A.-L., Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology. 99:1989;S28-S31.
12. Fink J.S., Smith G.P. Mesolimbic and mesocortical dopaminergic neurons are necessary for normal exploratory behavior in rats. Neurosci Lett. 17:1980;61-65.
13. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., et al. VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 46:1994;157-203.
14. Janssen P.A.J., Niemegeers C., Awouters F., Schellekens K.H.L., Megens A.A.H.P., Meert T.F. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 244:1988;685-693.
15. Janssen P.A.J., Niemegeers C., Schellekens K.H.L. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part III The subcutaneous and oral activity in rats and dogs of 56 neuroleptic drugs in the jumping box test . Arzneimittel Forschung. 16:1966;339-346.
16. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
17. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
18. 2 receptors in the rat brain. Biochem Pharmacol. 34:1985;2251-2259.
19. 2 antagonist. Mol Pharmacol. 27:1985;600-611.
20. Li C.C. Introduction to Experimental Statistics. 1964;McGraw-Hill, New York.
21. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 96:1949;99-113.
22. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine The dopamine-serotonin hypothesis of schizophrenia . Psychopharmacology. 99:1989;S18-S27.
23. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 3:1995;64-75.
24. Meltzer H.Y. Atypical antipsychotic drugs. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;1277-1286 Raven Press, New York.
25. Morpurgo C. Antiparkinson drugs and neuroleptics. Himwich W.A., Schadé J.P. Progress in Brain Res. vol 16:1965;121-134 Elsevier, Amsterdam.
26. 2A antagonist. Behav Brain Res. 73:1996;163-167.
27. O'Neill M.F., Palacios J.M. What makes atypical antipsychotics atypical? The case for serotonergic mechanisms of action. Exp Opin Invest Drugs. 3:1994;1317-1321.
28. Ponsluns D. An analysis of chlorpromazine-induced suppression of the avoidance response. Psychopharmacology. 3:1962;361-373.
29. Reynolds G.P., Czudek C. New approaches to the drug treatment of schizophrenia. Adv Pharmacol. 32:1995;461-503.
30. 2 receptor blocker. Drug Dev Res. 8:1986;205-211.
31. Sanger D.J. The effects of clozapine on shuttle-box avoidance responding in rats Comparisons with haloperidol and chlordiazepoxide . Pharmacol Biochem Behav. 23:1984;231-236.
32. 2 receptors exert a state dependent regulation of dopaminergic function Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine . Eur J Pharmacol. 223:1992;65-74.
33. Schmidt C.J., Kehne J.H., Carr A.A., Fadayel G.M., Humphreys T.M., Kettler H.J., et al. Contribution of serotonin neurotoxins to understanding psychiatric disorders The role of 5-HT2 receptors in schizophrenia and antipsychotic activity . Int Clin Psychopharmacol. 8:1993;25-32.
34. Seeman P. Receptor selectivities of atypical neuroleptics. Meltzer H.Y. Novel Antipsychotic Drugs. 1992;145-154 Raven Press, New York.
35. Siegel S., Castellan N.J. Jr. Nonparametric Statistics for the Behavioral Sciences. 1988;McGraw-Hill, New York.
36. Sipes T.E., Geyer M.A. DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors. Behav Pharmacol. 6:1995;839-842.
37. Stevens J.R. An anatomy of schizophrenia? Arch Gen Psychiatry. 29:1973;177-189.
38. 2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic Behavioral, electrophysiological and neurochemical studies . J Pharmacol Exp Ther. 266:1993;684-691.
39. 2 antagonism. Vanhoutte P.M., Saxena P.R., Paoletti R., Brunello N., Jackson A.S. Serotonin From Cell Biology to Pharmacology and Therapeutics . 1993;263-276 Kluwer Academic Publishers, Dordrecht.
40. Wadenberg M.-L., Ericson E.L., Magnusson O., Ahlenius S. Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biol Psychiatry. 28:1990;297-307.
41. Wadenberg M.-L., Ahlenius S., Svensson T.H. Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists Implications for the mechanism of action of clozapine . Psychopharmacology. 110:1993;273-279.
42. 2 receptor blocking agent ritanserin in the rat. Eur Neuropsychopharmacol. 6:1996;305-310.
43. Wadenberg M-L, Hicks PB, Young KA, Richter JT (1997): Further evidence for a role of the 5-HT2A receptor in the mediation of antipsychotic-like activity in rats. International Congress on Schizophrenia Research; Colorado Springs, CO; Abstract.